Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Plan B Decision To Be Guided By Public Comments, Deputy Commissioner Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is awaiting comments about the “legal authority and regulatory pathway” for marketing an active ingredient both as a prescription and OTC drug, Deputy Commissioner Gottlieb says.

You may also be interested in...

Crawford Resigns; NCI Director Von Eschenbach Named To Top FDA Spot

Von Eschenbach appointed to be acting FDA commissioner following the Sept. 23 resignation of Lester Crawford.

FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs

Agency initiates advance notice of proposed rulemaking to determine whether an active drug ingredient can be marketed both Rx and OTC for the same indication.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts